Inno Biopharmaceuticals

Inno Biopharmaceuticals (commonly known as Inno Biologics) is a Malaysian government-backed biotechnology company focused on the development and manufacturing of biopharmaceuticals. Established in 2002 as a national strategic initiative, the company operates a state-of-the-art cGMP facility in Nilai, Negeri Sembilan, which was the first modular biopharmaceutical production plant in the country. The company specializes in mammalian cell culture technology for the production of monoclonal antibodies and recombinant proteins, offering contract development and manufacturing (CDMO) services to international and local clients. In addition to its CDMO operations, Inno Biopharmaceuticals maintains a pipeline of biosimilar products targeting indications such as multiple sclerosis and oncology-related neutropenia. As a central pillar of Malaysia's biotechnology ecosystem, the company aims to enhance regional capacity for advanced biologics production and therapeutic innovation.